ChemoCentryx (CCXI) to Offer Common Stock

ChemoCentryx, Inc. (Nasdaq: CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. SVB Leerink and Piper Sandler are acting as joint bookrunning managers for the offering. All shares of the common stock to be sold in the offering will be offered by ChemoCentryx. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

You May Also Be Interested In

• Nuvectis Pharma prices $100M public offering at $20 per share
• Vishay Intertechnology launches $750M common stock offering
• Raytech Holding closes $6.2 million direct offering of shares